Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) Vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients with Cirrhosis

Description

This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.

Conditions

Liver Cancer, Liver Cirrhoses, Liver Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.

Abbreviated MRI (AMRI) Vs. Ultrasound for HCC Surveillance in Cirrhosis

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) Vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients with Cirrhosis

Condition
Liver Cancer
Intervention / Treatment

-

Contacts and Locations

La Jolla

University of California, San Diego, La Jolla, California, United States, 92037

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject has been fully informed and has personally signed and dated the written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) documents.
  • * Adult subjects of any gender and any ethnic group with liver cirrhosis of any etiology,
  • * Subject is able and willing to complete required research procedures (screening/enrollment, clinical evaluation, safety procedures, lab collection if needed, research AMRI exam, research US exam) and the three optional surveys (if subject opts in for that) within specified time windows, and is willing to allow the study team to review clinical data including but not limited to other clinical radiology reports and images.
  • * VA patient
  • * \< 18 years of age
  • * History of any liver cancer
  • * MRI contraindication(s)
  • * Subject knows that she is pregnant or states she trying to become pregnant
  • * Positive urine pregnancy test in woman of childbearing potential
  • * Nursing mother
  • * Subject has known allergy to any gadolinium agent
  • * Does not meet UC San Diego Intravenous Contrast Media Guidelines for administration of Eovist\*
  • * Clinical screening exam of the liver performed at UCSD within the prior 90 days to consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, San Diego,

Claude B Sirlin, MD, PRINCIPAL_INVESTIGATOR, University of California, San Diego

Study Record Dates

2025-12-30